Nevro Corp (NYSE:NVRO) has been given an average rating of “Hold” by the eleven ratings firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $99.71.
A number of analysts recently weighed in on NVRO shares. Northland Securities restated a “buy” rating and set a $96.00 target price on shares of Nevro in a research note on Tuesday, November 7th. Canaccord Genuity restated a “buy” rating and set a $120.00 target price on shares of Nevro in a research note on Sunday, October 8th. BidaskClub lowered shares of Nevro from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Finally, Zacks Investment Research upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th.
Shares of Nevro (NYSE NVRO) opened at $77.40 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.81 and a current ratio of 8.78. Nevro has a one year low of $65.00 and a one year high of $99.63. The firm has a market cap of $2,290.00, a P/E ratio of -53.38 and a beta of -0.83.
Nevro (NYSE:NVRO) last released its earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.02. Nevro had a negative net margin of 7.57% and a negative return on equity of 10.30%. The firm had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. During the same period in the prior year, the firm earned ($0.14) earnings per share. The business’s quarterly revenue was up 35.0% compared to the same quarter last year. analysts predict that Nevro will post -1.27 EPS for the current fiscal year.
In other Nevro news, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 12.10% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in NVRO. Ameritas Investment Partners Inc. grew its position in shares of Nevro by 17.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 358 shares during the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Nevro during the second quarter worth approximately $190,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Nevro during the third quarter worth approximately $211,000. Prudential Financial Inc. grew its position in shares of Nevro by 13.8% during the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after acquiring an additional 350 shares during the last quarter. Finally, Sterling Capital Management LLC purchased a new position in shares of Nevro during the second quarter worth approximately $233,000.
COPYRIGHT VIOLATION NOTICE: “Nevro Corp (NVRO) Given Average Rating of “Hold” by Brokerages” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/19/nevro-corp-nvro-given-average-rating-of-hold-by-brokerages.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.